Filter posts

Points to Consider about the Center for American Progress Prescription Drug Discussion

This afternoon, the Center for American Progress (CAP) Action Fund hosted an obviously one-sided discussion …

Facing growing pressure, N.Y. insurers agree to lift restrictions on hepatitis c therapies

Last week, we wrote about the mounting evidence of insurer discrimination and coverage denials for …

ICYMI: One Patient’s Perspective: Having Cancer Doesn’t Make Me Worth Less

Yesterday, cancer survivor and health economist Jennifer Hinkel shared her perspective on the Institute for …

Patient and provider groups ask CMS: Don’t turn back the clock on rheumatic disease care

Writing today in The Hill, Ann Palmer of the Arthritis Foundation and Joan Von Feldt …

Evidence Mounts of Insurer Discrimination against HIV, HCV Patients

We’ve written before about the problem of discriminatory formulary design in health insurance plans, particularly …

New Reports: Insurance Plans Shifting More Costs to Patients

A new report out this week from the Kaiser Family Foundation showed that patient out …

Morning Consult: Medicare’s Flawed Part B Drug Experiment Could Harm Patients

In today’s Morning Consult, the Community Oncology Alliance’s Rose Gerber has an excellent piece detailing …

Judd Gregg: Biodefense Funding Is Crucial to National Security

Writing in the Morning Consult, former Senator Judd Gregg explains critical role of federal programs …

JAMA Study Finds Vast Majority of Requests for Clinical Trial Data Granted

In 2014, BIO members reaffirmed and broadened their commitment to responsibly share data from clinical …

ICYMI: John Lechleiter: An Empty Obama-Clinton-Sanders Plan on Drug Costs

Writing in the Wall Street Journal today, Eli Lilly and Company Chairman, President and CEO …